Opioid use disorder, is the continued use of an opioid that causes clinically significant distress or impairment and use of buprenorphine reduces mortality.
Buprenorphine Drug : Cuts Down Opioid Withdrawal Symptoms to Nearly Half in Infants
Opioid withdrawal in infants can be cut down to nearly half by using buprenorphine drug, finds study.
Opioid withdrawal in infants can be cut down to nearly half by using buprenorphine drug, finds study.
‘Buprenorphine, an opioid drug used to treat opioid addiction, moderate acute pain and moderate chronic pain should be administered to patients without any interruptions during treatment.’
The mortality rate for study subjects was 0.63/100 person-year [95 percent CI 0.40- 0.85], compared to 0.24/100 person-year [0.24-0.25] for other individuals of the same age range during the same time period. The authors encourage physicians to avoid interruption of treatment and encourage patients to remain in treatment for a sufficient amount of time.
Increased Use of Buprenorphine Poses Serious Danger for Accidental Exposure Among Children
Researchers have warned that the increased use of buprenorphine is leading to increased number of accidental exposure among children.
Researchers have warned that the increased use of buprenorphine is leading to increased number of accidental exposure among children.
For Prescription Drug Addiction Treatment, Buprenorphine Maintenance Trumps Detoxification: Study
For treating patients with prescription opioid dependence in primary care, buprenorphine maintenance therapy is superior to detoxification, according to a new study by Yale School
For treating patients with prescription opioid dependence in primary care, buprenorphine maintenance therapy is superior to detoxification, according to a new study by Yale School
Factors Associated With Discontinuation of Treatment for Opioid Dependence
Many individuals who participate in Office Based Addiction Treatment (OBAT) with buprenorphine discontinue treatment less than one year after initiation.
Many individuals who participate in Office Based Addiction Treatment (OBAT) with buprenorphine discontinue treatment less than one year after initiation.
